TCF7L2-rs7903146 polymorphism modulates the effect of artichoke leaf extract supplementation on insulin resistance in metabolic syndrome: a randomized, double-blind, placebo-controlled trial.
- 2018-09
- Journal of integrative medicine 16(5)
- Mehranghiz Ebrahimi-Mameghani
- Mohammad Asghari-Jafarabadi
- Khatereh Rezazadeh
- PubMed: 30177026
- DOI: 10.1016/j.joim.2018.05.006
Study Design
- Type
- Randomized Controlled Trial (RCT)
- Sample size
- n = 80
- Population
- 80 patients with MetS in Sina Clinic, Khoy, Iran
- Methods
- Double-blind clinical trial, randomized into ALE or placebo groups to receive either ALE (1800 mg/d as four tablets) or matching placebo for 12 weeks
- Blinding
- Double-blind
- Duration
- 12 weeks
- Funding
- Unclear
Background
Transcription factor 7-like 2 (TCF7L2)-rs7903146 polymorphism is associated with increased risk of type 2 diabetes. The response of insulin and insulin resistance to artichoke leaf extract (ALE) may be affected by TCF7L2-rs7903146 polymorphism.Objective
This study examined the effects of ALE supplementation on metabolic parameters of the TCF7L2-rs7903146 polymorphism in patients with metabolic syndrome (MetS).Design, setting, participants and interventions
This double-blind clinical trial was conducted on 80 patients with MetS in Sina Clinic, Khoy, Iran. The patients were randomized into ALE or placebo groups to receive either ALE (1800 mg/d as four tablets) or matching placebo for 12 weeks.Main outcome measures
Anthropometric indices, blood pressure, glucose and lipid profile levels were measured before and after the study. Moreover, patients were genotyped for TCF7L2 polymorphism.Results
ALE supplementation decreased insulin level and the homeostasis model assessment of insulin resistance (HOMA-IR) in patients with the TT genotype of TCF7L2-rs7903146 polymorphism (P < 0.05). There was no significant interaction between blood pressure, glucose and lipid profile response to ALE supplementation.Conclusion
The responses of insulin and HOMA-IR to ALE supplementation have shown an interaction with single-nucleotide polymorphism rs7903146 in TCF7L2.Trial registration
Iranian Registry of Clinical Trial IRCT201409033320N9.Research Insights
There was no significant interaction between blood pressure, glucose and lipid profile response to ALE supplementation.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 1800 mg/d as four tablets
ALE supplementation decreased insulin level and the homeostasis model assessment of insulin resistance (HOMA-IR) in patients with the TT genotype of TCF7L2-rs7903146 polymorphism (P < 0.05).
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1800 mg/d as four tablets
There was no significant interaction between blood pressure, glucose and lipid profile response to ALE supplementation.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 1800 mg/d as four tablets
There was no significant interaction between blood pressure, glucose and lipid profile response to ALE supplementation.
- Effect
- Neutral
- Effect size
- Small
- Dose
- 1800 mg/d as four tablets
ALE supplementation decreased insulin level and the homeostasis model assessment of insulin resistance (HOMA-IR) in patients with the TT genotype of TCF7L2-rs7903146 polymorphism (P < 0.05).
- Effect
- Beneficial
- Effect size
- Small
- Dose
- 1800 mg/d as four tablets